225 Second Avenue
About BioverativLaunching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.
CEO: John Cox
66 articles about Bioverativ
ALPROLIX Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study
The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when compared with conventional factor IX and a glycoPEGylated factor IX analog.
U.S. Label Update for Bioverativ's ALPROLIX Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children With Hemophilia B
These updates are based on interim data from the Phase 3 B-YOND open-label extension trial and final data from the Phase 3 Kids B-LONG pediatric study.
Bioverativ Release: Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment With ELOCTATE
Interim data show participants enrolled in the ASPIRE extension study demonstrated continuous improvement in joint health over a nearly three-year period with prophylactic dosing of ELOCTATE.
Bioverativ Reports Third Quarter 2017 Performance
Bioverativ Inc. today reported financial results for the third quarter of 2017.
Bioverativ To Report Third Quarter 2017 Financial Results On October 26, 2017
Tiny Bicycle Therapeutics Wrangles a $424 Million R&D Pact With Biogen Spinoff Bioverativ
Bioverativ And Invicro Form Novel, Advanced Imaging Collaboration Focused On Improving Management Of Joint Health In People With Hemophilia
Bioverativ Reports Second Quarter 2017 Performance
Why Biogen Spinoff Bioverativ's Anemia Drug Could Be A Blockbuster
Bioverativ To Report Second Quarter 2017 Financial Results On August 2, 2017
New Data To Be Presented At Isth Underscore Bioverativ’s Commitment To Advance Hemophilia Care
Bioverativ And Swedish Orphan Biovitrum Highlight Commitment To Improving Care For People With Hemophilia At ISTH 2017 Congress
Bioverativ Completes Acquisition Of True North
Bioverativ Announces FDA Acceptance Of Investigational New Drug Application For BIVV001 To Treat Hemophilia A
Biogen Spinoff Bioverativ Takes Out Bay Area's True North in $825 Million Deal
Bioverativ Appoints Geno J. Germano To Company’s Board Of Directors
Bioverativ Reports First Quarter 2017 Results
Bioverativ Appoints Tim Harris Executive Vice President, Research And Development
Bioverativ To Report First Quarter 2017 Financial Results On May 3, 2017
How Biogen Spinoff Bioverativ and Its Hemophilia Med Could Make This Biotech Bleed